Paul M. Rivard discusses the Supreme Court’s decision in the Myriad case in Genetic Engineering & Biotechnology News

June 19, 2013

Mr. Rivard discusses Association for Molecular Pathology et al. v. Myriad Genetics Inc. et al., a case involving the eligibility of Myriad’s patent claims to isolated DNA encoding BRCA 1 polypeptides, in a Genetic Engineering & Biotechnology News article titled, “A Myriad of Winners: Industry stands to benefit from Supreme Court gene-patenting decision.” The Court held that natural isolated DNA is not patent-eligible, while synthetically made complementary DNA (cDNA) is patent-eligible.

Please click here to read the article.

Posted: June 19, 2013

Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page